NCT00590629View on ClinicalTrials.gov

Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Coronary Artery Disease
Interventions
DRUG

Niaspan

1500 mg Niaspan for 16 weeks

Trial Locations (1)

90048

CSMC, Los Angeles

Sponsors
All Listed Sponsors
collaborator

General Clinical Research Center (GCRC)

UNKNOWN

collaborator

Kos Pharmaceuticals

INDUSTRY

lead

Cedars-Sinai Medical Center

OTHER